Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

Shillingford JM, Piontek KB, Germino GG, Weimbs T.

J Am Soc Nephrol. 2010 Mar;21(3):489-97. doi: 10.1681/ASN.2009040421. Epub 2010 Jan 14.

2.

Therapeutic advances in the treatment of polycystic kidney disease.

Riella C, Czarnecki PG, Steinman TI.

Nephron Clin Pract. 2014;128(3-4):297-302. doi: 10.1159/000368244. Epub 2015 Jan 6. Review.

3.

Apoptosis in polycystic kidney disease.

Goilav B.

Biochim Biophys Acta. 2011 Oct;1812(10):1272-80. doi: 10.1016/j.bbadis.2011.01.006. Epub 2011 Jan 15. Review.

4.
5.

Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1312-29. doi: 10.2215/CJN.01360210. Epub 2010 May 24. Review.

6.

mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.

Huber TB, Walz G, Kuehn EW.

Kidney Int. 2011 Mar;79(5):502-11. doi: 10.1038/ki.2010.457. Epub 2010 Nov 17. Review.

7.

Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.

Bastos AP, Onuchic LF.

Braz J Med Biol Res. 2011 Jul;44(7):606-17. Epub 2011 May 27. Review.

8.

The genetics and physiology of polycystic kidney disease.

Calvet JP, Grantham JJ.

Semin Nephrol. 2001 Mar;21(2):107-23. Review.

PMID:
11245774
9.

Translational research in ADPKD: lessons from animal models.

Happé H, Peters DJ.

Nat Rev Nephrol. 2014 Oct;10(10):587-601. doi: 10.1038/nrneph.2014.137. Epub 2014 Aug 19. Review.

PMID:
25137562
10.

Mouse models of polycystic kidney disease.

Wilson PD.

Curr Top Dev Biol. 2008;84:311-50. doi: 10.1016/S0070-2153(08)00606-6. Review.

PMID:
19186247
11.

Molecular genetics of polycystic kidney disease.

Calvet JP.

J Nephrol. 1998 Jan-Feb;11(1):24-34. Review.

PMID:
9561482
12.

mTOR signaling in polycystic kidney disease.

Ibraghimov-Beskrovnaya O, Natoli TA.

Trends Mol Med. 2011 Nov;17(11):625-33. doi: 10.1016/j.molmed.2011.06.003. Epub 2011 Jul 19. Review.

PMID:
21775207
13.

Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells.

Zheleznova NN, Wilson PD, Staruschenko A.

Biochim Biophys Acta. 2011 Oct;1812(10):1301-13. doi: 10.1016/j.bbadis.2010.10.004. Epub 2010 Oct 16. Review.

14.

Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.

Kim HJ, Edelstein CL.

Kidney Res Clin Pract. 2012 Sep;31(3):132-8. doi: 10.1016/j.krcp.2012.07.002. Epub 2012 Aug 10. Review.

15.

[Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].

Covic M, Covic M.

Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):11-20. Review. Romanian.

PMID:
18677899
16.

Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.

Lieberthal W, Levine JS.

Am J Physiol Renal Physiol. 2012 Jul 15;303(2):F180-91. doi: 10.1152/ajprenal.00015.2012. Epub 2012 Apr 11. Review.

17.

Drug discovery for polycystic kidney disease.

Sun Y, Zhou H, Yang BX.

Acta Pharmacol Sin. 2011 Jun;32(6):805-16. doi: 10.1038/aps.2011.29. Review.

18.

Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?

Weimbs T.

Cell Cycle. 2006 Nov 1;5(21):2425-9. Epub 2006 Sep 13. Review.

PMID:
17102641
19.

The molecular biology of polycystic kidney disease.

Murcia NS, Woychik RP, Avner ED.

Pediatr Nephrol. 1998 Nov;12(9):721-6. Review.

PMID:
9874315
20.

What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?

Edelstein CL.

Cell Cycle. 2005 Nov;4(11):1550-4. Epub 2005 Nov 17. Review.

PMID:
16258272
Items per page

Supplemental Content

Write to the Help Desk